Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yingyi Wu

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
EMBO Molecular Medicine|February 8, 2021
NF45/NF90-mediated rDNA transcription provides a novel target for immunosuppressant developmentHsiang-I Tsai, Xiaobin Zeng, Longshan Liu, et al.
Med (New York, N.Y.)|May 30, 2025
Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remissionDandan Wang, Xiaobing Wang, Binghe Tan, et al.
Biomaterials Science|December 28, 2020
PD-L1 cellular nanovesicles carrying rapamycin inhibit alloimmune responses in transplantationMin Yang, Zhanxue Xu, Hailan Yan, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|November 5, 2021
Engineered Small Extracellular Vesicles as a FGL1/PD-L1 Dual-Targeting Delivery System for Alleviating Immune RejectionHsiang-I Tsai, Yingyi Wu, Xiaoyan Liu, et al.
Journal of Hepatology|June 20, 2026
MRI-based prediction of very early recurrence within 1 year after resection of HCC: An international cohort studyHong Wei, Subin Heo, Yang Yang, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
EMBO Molecular Medicine|February 8, 2021
NF45/NF90-mediated rDNA transcription provides a novel target for immunosuppressant developmentHsiang-I Tsai, Xiaobin Zeng, Longshan Liu, et al.
Med (New York, N.Y.)|May 30, 2025
Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remissionDandan Wang, Xiaobing Wang, Binghe Tan, et al.
Biomaterials Science|December 28, 2020
PD-L1 cellular nanovesicles carrying rapamycin inhibit alloimmune responses in transplantationMin Yang, Zhanxue Xu, Hailan Yan, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|November 5, 2021
Engineered Small Extracellular Vesicles as a FGL1/PD-L1 Dual-Targeting Delivery System for Alleviating Immune RejectionHsiang-I Tsai, Yingyi Wu, Xiaoyan Liu, et al.
Journal of Hepatology|June 20, 2026
MRI-based prediction of very early recurrence within 1 year after resection of HCC: An international cohort studyHong Wei, Subin Heo, Yang Yang, et al.
Pageof 5